RedHill Biopharma (RDHL) Current Deferred Revenue (2018 - 2025)

RedHill Biopharma (RDHL) has 8 years of Current Deferred Revenue data on file, last reported at $6.3 million in Q4 2025.

• Current Deferred Revenue for Q4 2025 came in at $6.3 million, down 32.13% year-over-year; the trailing twelve-month figure through Dec 2025 was $6.3 million (down 32.13% YoY), and the FY2025 annual result was $6.3 million, down 32.13% from the prior year.
• Current Deferred Revenue fell to $6.3 million in Q4 2025 per RDHL's latest filing, from $10.5 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $47.9 million in Q4 2022 and troughed at $6.3 million in Q4 2025.
• A 5-year average of $24.0 million and a median of $26.0 million in 2023 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2021 and 2023: Current Deferred Revenue jumped 67.43% in 2021, then slumped 77.74% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $30.7 million in 2021, then jumped by 55.87% to $47.9 million in 2022, then tumbled by 77.74% to $10.7 million in 2023, then slipped by 12.82% to $9.3 million in 2024, then plunged by 32.13% to $6.3 million in 2025.
• Business Quant data shows RDHL's Current Deferred Revenue at $6.3 million in Q4 2025, $10.5 million in Q2 2025, and $9.3 million in Q4 2024.